Robert Conry

Robert Conry

UNVERIFIED PROFILE

Are you Robert Conry?   Register this Author

Register author
Robert Conry

Robert Conry

Publications by authors named "Robert Conry"

Are you Robert Conry?   Register this Author

41Publications

845Reads

17Profile Views

Correlates of response and outcomes with talimogene laherperpvec.

J Surg Oncol 2019 Sep 2;120(3):558-564. Epub 2019 Jul 2.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25601DOI Listing
September 2019

Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.

JAAD Case Rep 2019 Sep 29;5(9):782-786. Epub 2019 Aug 29.

Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.06.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728723PMC
September 2019

Sorafenib for Advanced and Refractory Desmoid Tumors.

N Engl J Med 2018 12;379(25):2417-2428

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center (M.M.G., W.D.T., N.H., N.P.A., R.A.L., Y.M., R.Y.) and Columbia University Vagellos College of Physicians and Surgeons and New York Presbyterian Hospital (L.H.S., G.K.S.), New York, and Northwell Cancer Institute and Cold Spring Harbor Laboratory, Lake Success (R.G.M.) - all in New York; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (M.R.M.); Washington University School of Medicine, St. Louis (B.A.V.T.); M.D. Anderson Cancer Center, University of Texas, Houston (V.R.); Mayo Clinic in Florida, Jacksonville (S.A.); Yale University, New Haven, CT (H.A.D.); University Health Network Princess Margaret Cancer Centre, Toronto (A.A.G.); University of Iowa-Holden Comprehensive Cancer Center, Iowa City (M.M.M.); University of Alabama at Birmingham Cancer Center, Birmingham (R.M.C.); Fox Chase Cancer Center, Philadelphia (S.M.); Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC (M.J.P.); Duke Cancer Institute, Duke University Medical Center, Durham (R.F.R.), and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill (E.B.) - both in North Carolina; Dayton National Cancer Institute Community Oncology Research Program, Dayton, OH (T.S.); National Cancer Institute, Bethesda, MD (J.J.W.); and the Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ (A.C.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447029PMC
December 2018

Talimogene laherparepvec: First in class oncolytic virotherapy.

Hum Vaccin Immunother 2018 04 22;14(4):839-846. Epub 2018 Feb 22.

b Medicine, University of Alabama at Birmingham , Birmingham , AL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2017.1412896DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893211PMC
April 2018

Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?

Radiol Case Rep 2018 Feb 20;13(1):89-91. Epub 2017 Oct 20.

Department of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radcr.2017.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850905PMC
February 2018

Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.

J Cutan Pathol 2018 Jan 26;45(1):48-53. Epub 2017 Oct 26.

Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13048DOI Listing
January 2018

Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.

J Immunother 2016 Nov/Dec;39(9):373-378

*Department of Radiation Oncology †Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072829PMC
December 2017

Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy.

Clin Sarcoma Res 2017 14;7:14. Epub 2017 Jul 14.

Division of Hematology Oncology, University of Alabama at Birmingham, 2145 Bonner Way, Birmingham, AL 35243 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13569-017-0079-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513342PMC
July 2017

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.

JAAD Case Rep 2017 May 14;3(3):185-189. Epub 2017 Apr 14.

Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2017.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394182PMC
May 2017

Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.

Melanoma Res 2017 04;27(2):159-163

aCovenant College, Lookout Mountain, Georgia bComprehensive Cancer Center cDivision of Hematology Oncology, University of Alabama dDepartment of Radiology, General Radiology and Cardiopulmonary Section, UAB Medicine, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000318DOI Listing
April 2017

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

J Clin Oncol 2017 Mar 30;35(8):885-892. Epub 2017 Jan 30.

Sanjiv S. Agarwala, Saint Luke's University Hospital, Easton; Uma N. Rao, Ahmad A. Tarhini, Terry L. Evans, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra J. Lee, and Waiki Yip, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD; Douglas S. Reintgen, Lakeland Regional Cancer Center, Lakeland; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL; Joanna M. Brell, MetroHealth Medical Center, Cleveland; William E. Carson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mark R. Albertini, University of Wisconsin Hospital, Madison, WI; Michael B. Atkins, Georgetown Medical Center, Washington, DC; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Robert M. Conry, University of Alabama at Birmingham, Birmingham, AL; Jeffrey A. Sosman, Vanderbilt University, Nashville; Alberto S. Pappo, Saint Jude Children's Research Hospital Oncology, Memphis, TN; Lawrence E. Flaherty, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Michael G. Smylie, Cross Cancer Institute, Edmonton, Canada; and Richard F. Kefford, Sydney West Area Health Service, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684PMC
March 2017

Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma.

Int J Surg Pathol 2016 Dec 14;24(8):753-756. Epub 2016 Jul 14.

University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1066896916658955DOI Listing
December 2016

Responses to immune checkpoint inhibitors in nonagenarians.

Oncoimmunology 2016 18;5(11):e1234572. Epub 2016 Oct 18.

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1234572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139628PMC
October 2016

Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.

Clin Sarcoma Res 2016 28;6. Epub 2016 Apr 28.

Department of Pediatrics, University of Alabama at Birmingham, 1600 7th Avenue South, Birmingham, AL 35233 USA ; Cancer & Blood Disorders Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13569-016-0046-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848872PMC
April 2016

Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.

Melanoma Res 2015 Jun;25(3):246-51

aSchool of Medicine bDepartment of Radiation Oncology cDepartment of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000154DOI Listing
June 2015

Ipilimumab-induced encephalopathy with a reversible splenial lesion.

Cancer Immunol Res 2015 Jun 28;3(6):598-601. Epub 2015 Apr 28.

Neuro-Oncology Program, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0035DOI Listing
June 2015

Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review.

Authors:
Robert M Conry

Clin Sarcoma Res 2014 28;4. Epub 2014 Jun 28.

Division of Hematology & Oncology, University of Alabama at Birmingham, 2145 Bonner Way, Birmingham, AL 35243, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2045-3329-4-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089565PMC
July 2014

Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.

Melanoma Res 2014 Jun;24(3):237-43

aDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas bDivision of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA cDermatology Polyclinic, Saint Louis Hospital, Paris dDepartment of Dermatology, Aix-Marseille University, Marseille, France eDepartment of Dermatology, University Medical Centre, Tubingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000056DOI Listing
June 2014

ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Clin Cancer Res 2013 Dec 11;19(23):6597-604. Epub 2013 Oct 11.

Authors' Affiliations: Gundersen Health System; Gundersen Medical Foundation, La Crosse, Wisconsin; Dana-Farber Cancer Institute, Boston, Massachusetts; University of Alabama Comprehensive Cancer Center, Birmingham, Alabama; and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859372PMC
December 2013

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.

Cancer Biother Radiopharm 2006 Dec;21(6):553-60

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2006.21.553DOI Listing
December 2006

A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.

Cancer Biother Radiopharm 2006 Dec;21(6):561-8

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2006.21.561DOI Listing
December 2006

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.

J Immunother 2005 Jul-Aug;28(4):382-8

University of Alabama at Birmingham Comprehensive Cancer Center, Alabama 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cji.0000162779.88687.4cDOI Listing
October 2005

Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

Clin Cancer Res 2002 Sep;8(9):2782-7

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama 35294-3300, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/8/9/2782.full.
Web Search
September 2002